Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
J Am Acad Dermatol
; 82(6): 1328-1336, 2020 Jun.
Article
em En
| MEDLINE
| ID: mdl-32135208
ABSTRACT
BACKGROUND:
Pruritus (itch) is a cardinal symptom in atopic dermatitis (AD).OBJECTIVE:
To evaluate the timing and effect of dupilumab on itch.METHODS:
Analysis of data from 1505 patients with moderate to severe AD included in 4 randomized controlled studies, treated for up to 52 weeks. Adults received dupilumab 300 mg every 2 weeks or placebo monotherapy (SOLO 1 NCT02277743; SOLO 2 NCT02277769), with concomitant topical corticosteroids (CHRONOS NCT02260986); adolescents (≥12 to <18 y) were treated with dupilumab monotherapy every 2 weeks (200 mg for baseline weight of <60 kg; 300 mg for baseline weight of ≥60 kg) or placebo (AD ADOL NCT03054428).RESULTS:
Dupilumab showed significant rapid improvements from baseline in daily Peak Pruritus Numerical Rating Scale scores versus placebo, by day 2 in adults and day 5 in adolescents. At treatment end, dupilumab vs placebo/control had greater least-squares mean percent change from baseline in the weekly average of Peak Pruritus Numerical Rating Scale scores SOLO -47.5% vs -20.5%; AD-ADOL -47.9% vs -19.0%; CHRONOS -57.3% vs -30.9% (P < .0001 for all).LIMITATIONS:
Short duration of monotherapy trials (16 weeks).CONCLUSION:
Across 4 randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Prurido
/
Dermatite Atópica
/
Fármacos Dermatológicos
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Adolescent
/
Adult
/
Humans
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2020
Tipo de documento:
Article